BioLineRx (NASDAQ:BLRX) Raised to “Sell” at StockNews.com

BioLineRx (NASDAQ:BLRX) was upgraded by analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a research report on Wednesday, April 17th.

BioLineRx Stock Performance

NASDAQ:BLRX opened at $0.68 on Tuesday. The firm’s fifty day moving average price is $1.05 and its 200 day moving average price is $1.32. BioLineRx has a 1-year low of $0.61 and a 1-year high of $2.53. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. The firm has a market cap of $54.13 million, a price-to-earnings ratio of -0.75 and a beta of 1.38.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $4.80 million during the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter last year, the business earned ($0.09) earnings per share. On average, sell-side analysts expect that BioLineRx will post -1.03 EPS for the current year.

Institutional Investors Weigh In On BioLineRx

Institutional investors have recently made changes to their positions in the stock. Rathbones Group PLC purchased a new stake in shares of BioLineRx during the 3rd quarter worth $72,000. B. Riley Wealth Advisors Inc. boosted its position in shares of BioLineRx by 88.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in shares of BioLineRx during the 3rd quarter worth $46,000. Values First Advisors Inc. purchased a new stake in shares of BioLineRx during the 3rd quarter worth $88,000. Finally, PVG Asset Management Corp purchased a new stake in shares of BioLineRx during the 4th quarter worth $97,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.